Alnylam reports positive results from ILLUMINATE-B phase 3 study of Lumasiran #Alnylam #Lumasiran “Alnylam Pharmaceuticals announced positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of #primaryHyperoxaluria type 1 (PH1). ILLUMINATE-B is now the seventh Phase 3 study of an RNAi therapeutic that has yielded positive results, and the first-ever study evaluating the safety and efficacy of this new class of medicines in children under the age of six, including infants.” #MSL #FSTP #MSLcert #medicalscienceliaison medical science liaison #Medicalaffairs medical affairs #Pharmacist #PHD #postdoclife https://www.instagram.com/p/CF5g_tZDkG9/?igshid=q5ucqoci4gpf